Abstract
Introduction
Hepatic fibrosis results from a sustained wound healing response to chronic liver injury. Although even acute injury will activate mechanisms of fibrogenesis, the sustained signals associated with chronic liver disease caused by infection, drugs, metabolic disorders or auto-immune disease are required for the development of substantial fibrosis. Occasionally, fibrosis may be rapidly progressive over weeks to months, for example as a result of drug injury, hepatitis C infection after liver transplantation [1] , or hepatitis C coinfection with HIV [2] , but mostly fibrosis evolves over decades. Any chronic perturbation of hepatic homeostasis may elicit signals necessary to stimulate fibrogenesis [3] . The [3, 5] . The essential difference between cirrhosis and (developing) fibrosis is that during cirrhosis more scar tissue is formed that distorts the liver parenchyma.
viral hepatitis) or centro-portal bridging (e.g. alcoholic liver disease). Irrespective of the actual location of the lesions, hepatic fibrosis is characterized by several key features: (1) the persistence of chronic damage to hepatocytes and/or cholangiocytes, (2) a complex inflammatory cell infiltrate and (3) activation of different types of ECM-producing cells with proliferative and synthetic features, finally leading to (4) marked changes in the quality and quantity of the hepatic ECM that distort the hepatic architecture and lead to an impairment of organ function

Activation of the coagulation cascade during liver fibrosis: a puzzling paradox
A common feature of fibrotic disease of various organs is the activation of the coagulation cascade [6, 7] . Accordingly, a local hypercoagulable state also accompanies liver fibrosis. Strikingly, patients diagnosed with liver fibrosis frequently also present with systemic coagulation deficiency [8] (Fig. 2D-F [65, 66] . FXa-induced PAR-2 activation also leads to the release of PAI-1 and transforming growth factor (TGF)-␤ (a powerful profibrotic cytokine) in both human mesangial cells and in embryonic fibroblasts [50, 65] . Finally, FXa acts as a powerful chemoattractant for murine embryonic fibroblasts and contributes to differentiation of these fibroblasts into myofibroblasts [65] . [67, 68] . These activated HSCs subsequently induce profibrotic responses [3] .
thrombin signals through PAR-1, -3 and -4, FVIIa in association with tissue factor activates PAR-2, while FXa activates both PAR-1 and PAR-2 [41]. Coagulation factor driven PAR activation thus establishes a potential link between activation of the coagulation cascade and the progression of fibrosis. This link might be most relevant for FXa as this coagulation factor occupies a unique position at the crossroads between coagulation and signalling. On the one hand, FXa leads to thrombin generation via its procoagulant properties after which thrombin induces profibrotic responses via PAR-1 activation. On the other hand, FXa induces fibrotic responses by PAR-2 dependent signalling in a way which is not reminiscent of thrombin signalling. The importance of thrombin-induced PAR-1 activation in liver fibrosis has been established recently (for review, see [42]); however, the role of PAR-2 and the cellular consequences of its activation by coagulation FXa has remained remarkably underexplored in the context of liver fibrosis. This is mainly because it has long
Expression and distribution of human PAR-2 in normal and pathological liver tissue
The liver lobule is formed by parenchymal cells, i.e. hepatocytes, and non-parenchymal cells. In contrast to hepatocytes that occupy most of the total liver volume and perform the majority of liver functions, non-parenchymal liver cells contribute only to a minor portion of the liver volume, but they make up almost 40% to the total number of liver cells. These non-parenchymal cells include
Direct proof for the importance of FXa-dependent PAR-2 signalling in portal fibroblasts and/or other resident fibroblasts during hepatic fibrosis has not yet been obtained. However, as already indicated, PAR-2 is expressed on these cell types in fibrotic liver tissue (Fig. 2). It is therefore tempting to speculate that FXa signalling indeed activates hepatic fibroblasts and consequently aggravates fibrosis.
FXa triggers pro-inflammatory responses and modulates the survival of epithelial cells via PAR-2 activation
The liver contains two relevant epithelial cell types: hepatocytes and cholangiocytes (epithelial cells of the bile duct). The contribution
Fig. 2 Immunostaining for PAR-2 in normal and cirrhotic human liver. (A-C) In normal liver, a very intense PAR-2 staining is present in hepatocytes (A, 100ϫ), and more weakly in the endothelium of larger vessels (B, **, 400ϫ), and in bile duct epithelial cells (B, *). Staining was strong in KCs (C, arrows, 400ϫ). (D-F). In fibrotic liver, PAR-2 staining remained strong in hepatocytes in regenerative nodules (D, 40ϫ). Staining was strongly increased in the epithelium of newly formed biliary structures (E, arrows, 100ϫ) and in the endothelium and smooth muscle cells of small vascular structures (F, arrows, 400ϫ), compared with weaker staining in pre-existing bile ducts (E ϩ F,*).
of hepatocytes to liver fibrosis is considered to be mainly mediated by paracrine effects of the released inflammatory cytokines leading to the activation of HSCs and KCs. In addition, however, apoptotic hepatocytes are ingested by KCs leading to the release of TGF-␤ and subsequent HSC activation
Activated cholangiocytes also activate HSCs by the secretion of pro-inflammatory and chemotactic proteins. In addition, proliferation of the cholangiocytes also aggravates fibrosis [5] . [41, [77] [78] [79] [80] [81] [82] . Interestingly, PAR-2 expression is strongly up-regulated on cholangiocytes in fibrotic liver tissue (Fig. 2) and it is thus tempting to speculate that PAR-2 activation will lead to cholangiocyte proliferation thereby aggravating fibrosis. [84, 85] . PAR-2 activation also enhances the adhesion of peripheral blood mononuclear cells to endothelial cells [70] . Furthermore, PAR-2 activation in the lung induces airway constriction, lung inflammation and protein-rich pulmonary oedema [86] . Accordingly, PAR-2 deficiency reduces inflammation and mortality in different mouse models of inflammation [84, 87, 88] . Also, FXa signalling in leucocytes induces tissue factor expression [89] , as well as IL-1, IL-6, IL-8, MCP-1 and CCR-2 release [66, [90] [91] [92] . Interestingly, FXa enhances neutrophil chemoattractant production after ischaemia/reperfusion in the rat liver [93] . Taken together, these observations suggest that the prominent expression of PAR-2 on KCs is potentially related to, or underlies, the acute inflammatory response induced by FXa. [94] [95] [96] . Whether SECs might drive or initiate fibrosis, as has been suggested [94, 97] [108] . Finally, very recent data show that agonist peptide-driven PAR-2 activation triggers ROS generation by endothelial cells [109] . Indeed, oxidative stress plays an important role in producing liver damage and initiating hepatic fibrogenesis. Increased ROS is commonly detected in the liver of patients with chronic liver disease and in most types of experimental liver fibrosis [110, 111] . Therefore, it is tempting to speculate that the release of ROS following FXa-induced PAR-2 activation in the endothelium might further enhance the fibrotic response, for instance, by inducing apoptosis of hepatocytes, amplification of the inflammatory response as discussed in [110] , the production of profibrotic mediators from KCs or by fibroproliferative responses of (KC-) activated HSCs [112] .
Interestingly, the fact that PAR-2 mRNA expression is increased in cholangiocytes of bile duct ligated rats might suggest that PAR-2 activation in these cells would contribute to liver fibrosis [45]. PAR-2 expression in cholangiocytes does however not provide proof that its activation would contribute to fibrosis, and future experiments should pursue this hypothesis. Most likely because the concept of FXa signalling in pathology emerged only recently, the functional consequences of FXa signalling in liver epithelium and especially its potential pro-inflammatory role has never been investigated. However, the effects of FXainduced PAR-2 activation, especially with respect to pro-inflammatory responses, on different epithelial cells have been well described. For instance, FXa induces the activation of the pro-inflammatory transcription factor NF-B in HeLa cells (derived from cervix adenocarcinoma) [69], and the inflammatory cytokines such as IL-6, IL-8, MCP-1 or cyclooxygenase 2, respectively, in endothelial, mesangial and in epithelial and fibroblastic cell lines [70-72]. In addition, FXa-induced PAR-2 activation enhances PAI-1 gene induction and TGF-␤ production in epithelial kidney cells [50]. Next to inducing inflammation, FXa also modulates cell survival. While FXa induces PAR-1 dependent apoptosis in a broad range of epithelial cells [73-75] (which is consistent with thrombininduced apoptosis in epithelial cells [76]), FXa-dependent PAR-2 activation in cancer cells with an epithelial origin is generally associated with cell proliferation (this has for instance been shown using colon, cervix, breast, pancreas and skin cancer cells
FXa and PAR-2 signalling in inflammatory cells
KCs are the resident macrophages in the liver. They release a variety of inflammatory mediators, free radicals, fibrogenic cytokines, as well as ECM proteinases that alter the normal ECM structure during early stages of liver injury. As already indicated, KCs play a critical role in promoting HSC activation [83] and they express PAR-2 in fibrotic conditions. The relevance of PAR-2 expression on KCs in the progression of fibrosis might be supported by a recent study showing that sepsis-induced PAR-2 expression on KCs is correlated with an inflammatory response. Moreover, PAR-2 inhibition in this rat model of acute liver injury limits tumour necrosis factor-␣ production and improves outcome [47].
An overwhelming amount of data indicate that FXa and PAR-2 signalling trigger pro-inflammatory responses in inflammatory cells. Agonists of PAR-2 modulate neutrophil cytokine secretion, expression of cell adhesion molecules, rolling and migration
FX-induced PAR-2 activation modulates endothelial barrier permeability
SECs line the sinusoids and are in constant contact with sinusoidal blood flow and closely associated with hepatocytes, HSCs and KCs. Changes in SECs can already be detected before fibrosis using electron microscopy
Targeting FXa in animal models of liver fibrosis
Proof of concept for a role of FXa-PAR-2 signalling in liver fibrosis seems to be derived from rodent models of liver fibrosis in which different FXa inhibitors were used. Indeed, administration of the low molecular weight heparins enoxaparin, nadroparin and tinzaparin all significantly reduced liver fibrosis in a rat bile duct ligation model [113] . Moreover, dalteparin administration markedly ameliorated fibrosis in a rat model of carbon tetrachloride induced hepatic fibrogenesis. Importantly, however, it should be realized that targeting FXa also reduces downstream thrombin formation. Consequently, the reduced fibrotic response might not be solely FXa-PAR-2 dependent but also due to diminished thrombininduced PAR-1 signalling as this latter signalling pathway is known to be profibrogenic as well [42] . (2) and KCs (3) , it decreases barrier porosity in SECs (4) , and it leads to proliferation, migration, ECM production and differentiation into myofibroblasts of portal fibroblasts (5) and HSCs (6) . Moreover, FXa-induced paracrine activation of portal fibroblast (7) and HSCs (8) 
Summary and conclusions
